- AU$5.58m
- AU$4.97m
- AU$0.89m
- 35
- 82
- 34
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.49 | ||
| Price to Tang. Book | 43.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.59% | ||
| Return on Equity | -4.44% | ||
| Operating Margin | -20.75% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.93 | 1.27 | 1.01 | 0.96 | 0.89 | n/a | n/a | -26.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TrivarX Limited, formerly Medibio Limited, is an Australia-based mental health technology company engaged in the use of objective measures to aid in the early detection and screening of mental health conditions. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is development of artificial intelligence (AI)-driven, scientifically based devices for screening and diagnosis of behavioral health conditions. Its clinical research has enabled the development of proprietary algorithms for spectral analyses of sleep architecture and heart-rate variability. The Company’s lead product, MEB-001 analyses the data from a standard sleep study to identify depression at a sensitivity of over 85%. Its technology analyses the electrical signals from the brain and the heart to identify mental illness.
Directors
- Claude Solitario CEO
- Brian Mower CFO (45)
- Jeremy Schroetter CTO
- Archie Defillo OTH
- S. Stapelberg OTH
- Mathew Watkins SEC
- Peter Carlisle LED
- Lisa Ide NED
- Melanie Leydin NED
- Liwanag Ojala NED
- Lisa Wipperman Heine NED
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 5th, 1987
- Public Since
- January 29th, 2001
- No. of Employees
- 4
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 464,870,439
- Address
- Level 4, 100 Albert Road, SOUTH MELBOURNE, 3205
- Web
- https://medibio.com.au/
- Phone
- +61 861891155
- Auditors
- William Buck
Upcoming Events for TRI
Full Year 2025 TrivarX Ltd Earnings Release
Similar to TRI
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the TrivarX share price?
As of Today at 23:47 UTC, shares in TrivarX are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the TrivarX share price performed this year?
Shares in TrivarX last closed at AU$0.01 and the price had moved by -53.85% over the past 365 days. In terms of relative price strength the TrivarX share price has underperformed the ASX All Ordinaries Index by -55.52% over the past year.
What are the analyst and broker recommendations for TrivarX?
The overall consensus recommendation for TrivarX is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the TrivarX dividend yield?
TrivarX does not currently pay a dividend.
Does TrivarX pay a dividend?
TrivarX does not currently pay a dividend.
When does TrivarX next pay dividends?
TrivarX does not currently pay a dividend.
How do I buy TrivarX shares?
To buy shares in TrivarX you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of TrivarX?
As of the previous close price of AU$0.01, shares in TrivarX had a market capitalisation of AU$5.58m.
Where are TrivarX shares listed?
Here are the trading details for TrivarX:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: TRI
What kind of share is TrivarX?
Based on an overall assessment of its quality, value and momentum TrivarX is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a TrivarX share price forecast for 2025?
The analyst consensus target price for shares in TrivarX is AU$0.28. That is 2233.33% above the last closing price of AU$0.01.
Analysts covering TrivarX currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the TrivarX share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TrivarX. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -22.85%.
As of the last closing price of AU$0.01, shares in TrivarX were trading -37.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the TrivarX PE Ratio?
The TrivarX PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of TrivarX?
TrivarX's management team is headed by:
- Claude Solitario - CEO
- Brian Mower - CFO
- Jeremy Schroetter - CTO
- Archie Defillo - OTH
- S. Stapelberg - OTH
- Mathew Watkins - SEC
- Peter Carlisle - LED
- Lisa Ide - NED
- Melanie Leydin - NED
- Liwanag Ojala - NED
- Lisa Wipperman Heine - NED